JP2018500337A5 - - Google Patents

Download PDF

Info

Publication number
JP2018500337A5
JP2018500337A5 JP2017532675A JP2017532675A JP2018500337A5 JP 2018500337 A5 JP2018500337 A5 JP 2018500337A5 JP 2017532675 A JP2017532675 A JP 2017532675A JP 2017532675 A JP2017532675 A JP 2017532675A JP 2018500337 A5 JP2018500337 A5 JP 2018500337A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequences
acid sequence
cell
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017532675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018500337A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/067178 external-priority patent/WO2016100980A1/en
Publication of JP2018500337A publication Critical patent/JP2018500337A/ja
Publication of JP2018500337A5 publication Critical patent/JP2018500337A5/ja
Pending legal-status Critical Current

Links

JP2017532675A 2014-12-19 2015-12-21 炭酸脱水酵素ix特異的キメラ抗原受容体およびその使用方法 Pending JP2018500337A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462094596P 2014-12-19 2014-12-19
US62/094,596 2014-12-19
PCT/US2015/067178 WO2016100980A1 (en) 2014-12-19 2015-12-21 Carbonic anhydrase ix specific chimeric antigen receptors and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2018500337A JP2018500337A (ja) 2018-01-11
JP2018500337A5 true JP2018500337A5 (2) 2019-02-07

Family

ID=55273519

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017532675A Pending JP2018500337A (ja) 2014-12-19 2015-12-21 炭酸脱水酵素ix特異的キメラ抗原受容体およびその使用方法

Country Status (11)

Country Link
US (3) US10870705B2 (2)
EP (1) EP3233901A1 (2)
JP (1) JP2018500337A (2)
KR (1) KR20170093248A (2)
CN (1) CN108064251A (2)
AU (1) AU2015364240A1 (2)
BR (1) BR112017013177A2 (2)
CA (1) CA2968555A1 (2)
IL (1) IL252366A0 (2)
RU (1) RU2017125735A (2)
WO (1) WO2016100980A1 (2)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3233900A2 (en) * 2014-12-19 2017-10-25 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptors and methods of use thereof
AU2017382243A1 (en) * 2016-12-22 2019-05-02 Windmil Therapeutics, Inc. Compositions and methods for modulating the immune system
EP3747433A4 (en) 2018-02-02 2021-12-22 Cafa Therapeutics Limited COMBINATION OF CELL IMMUNOTHERAPY
CA3119644A1 (en) 2018-11-30 2020-06-04 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptor factories and methods of use thereof
CN109705225B (zh) * 2019-01-21 2022-02-22 徐州医科大学 一种抗人caix抗原的嵌合抗原受体及其应用
TWI869344B (zh) * 2019-05-06 2025-01-11 納維再生科技股份有限公司 抗-碳酸酐酶ix抗體
US12351645B2 (en) 2019-05-06 2025-07-08 Navi Bio-Therapeuticis, Inc. Anti-carbonic anhydrase IX antibody
CN116217728A (zh) 2019-09-10 2023-06-06 普米斯生物技术(珠海)有限公司 靶向caix抗原的纳米抗体及其应用
TWI793451B (zh) * 2019-09-20 2023-02-21 納維再生科技股份有限公司 個人化癌症免疫治療
CN113045665B (zh) * 2021-03-22 2022-05-13 徐州医科大学 一种hvem共刺激信号驱动的caix-car-t细胞及其制备方法和应用
CA3243979A1 (en) * 2022-02-11 2025-04-30 C-Biomex Co., Ltd. Peptide ligand targeting carbonic anhydrase IX, peptide construction comprising it, and associated uses
CN116102662A (zh) * 2022-10-10 2023-05-12 武汉波睿达生物科技有限公司 一种靶向ca9的融合嵌合抗原受体、重组表达载体及其应用
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9
WO2025064539A1 (en) 2023-09-19 2025-03-27 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Herv-e antibodies and methods of their use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
AU2005260732B2 (en) 2004-06-30 2011-08-25 Cardinal Health 529, Llc Intraluminal medical device having asymetrical members
US8466263B2 (en) * 2005-12-02 2013-06-18 Dana-Farber Cancer Institute, Inc. Carbonic anhydrase IX (G250) anitbodies
DE102008030837A1 (de) 2008-06-30 2010-01-14 Siemens Aktiengesellschaft Elektrochrome Formulierung, Herstellungsverfahren dazu und elektrochromes organisches Bauelement
FR2933058B1 (fr) 2008-06-30 2010-08-27 Zf Systemes De Direction Nacam Sas Dispositif d'assistance au verrouillage d'une colonne de direction
EP4282419A1 (en) * 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
WO2014165707A2 (en) * 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
FR3023477B1 (fr) 2014-07-10 2017-11-24 Oreal Utilisation cosmetique de l'acide spiculisporique comme actif deodorant

Similar Documents

Publication Publication Date Title
JP2018500337A5 (2)
RU2017125735A (ru) Химерные антигенные рецепторы против карбоангидразы ix и способы их применения
JP2019510733A5 (2)
JP2018504094A5 (2)
FI3703750T3 (fi) B-solujen maturaatioantigeenille spesifisiä kimeerisiä antigeenireseptoreita ja koodaavia polynukleotideja
JP2016508725A5 (2)
RU2018111462A (ru) Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
US20190151365A1 (en) Combination therapies of chimeric antigen receptors and pd-1 inhibitors
JP2018506981A5 (2)
JP2020530989A5 (2)
FI4063397T3 (fi) Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi
IL268620B2 (en) Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment
JP2017513478A5 (2)
JP2018508215A5 (2)
JP2017500869A5 (2)
JP2017508466A5 (2)
JP2015527070A5 (2)
RU2017137251A (ru) Комбинация антител cd30xcd16 для терапии с антагонистом pd-1
RU2018135247A (ru) БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК
JP2018532407A5 (2)
JP2017527275A5 (2)
JP2018518939A5 (2)
JP2015509717A5 (2)
RU2017121892A (ru) Клетка
JP2020512973A5 (2)